<DOC>
	<DOCNO>NCT00570713</DOCNO>
	<brief_summary>The purpose study investigate activity MORAb-009 add standard regimen gemcitabine patient previously untreated unresectable stage 3 4 pancreatic cancer .</brief_summary>
	<brief_title>An Efficacy Study MORAb-009 Subjects With Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Female male subject , ≥ 18 year age , cytologically histologically confirm diagnosis pancreatic adenocarcinoma . 2 . Must measurable disease , define RECIST evaluable clinical signs/symptoms ( e.g . ascites , pleural effusion , lesion less 2 cm ) support biomarker , radiologic , pathologic study conduct within 4 week prior study entry . 3 . Must unresectable disease receive prior chemotherapy radiation therapy pancreatic cancer . 4 . Karnofsky performance status great equal 70 % . 5 . Female subject childbearing potential male subject must surgically sterile consent use medically acceptable method contraception throughout study period . 6 . Other significant medical condition must wellcontrolled stable opinion investigator least 30 day prior Study Day 1 . 7 . Laboratory clinical result within 2 week prior Study Day 1 follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL Serum bilirubin ≤ 2.0 mg/dL Aspartate transaminase ( AST ) * ≤ 5 x upper limit normal ( ULN ) Alanine transaminase ( ALT ) * ≤ 5 x ULN Alkaline phosphatase* ≤ 5 x ULN Serum creatinine ≤ 2.0 mg/dL Stenting reduce liver function qualify level permit . * Subjects liver function abnormality great ULN eligible opinion investigator due disease obstruction bile ducts metastatic disease . 8 . Must willing able provide write informed consent . 1 . Known central nervous system ( CNS ) tumor involvement . 2 . Evidence active malignancy require treatment . 3 . Clinically significant heart disease ( e.g. , congestive heart failure New York Heart Association Class 3 4 angina well controlled medication , myocardial infarction within 6 month ) . 4 . Electrocardiogram ( ECG ) demonstrate clinically significant arrhythmia ( Note : Subjects chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia [ SVT ] , eligible ) . 5 . Active serious systemic disease , include active bacterial fungal infection . 6 . Active viral hepatitis symptomatic human immunodeficiency virus ( HIV ) infection . 7 . Prior chemotherapy radiation therapy pancreatic cancer . 8 . Breastfeeding , pregnant , likely become pregnant study . 9 . No concurrent immunotherapy ( e.g. , immunosuppressant chronic use systemic corticosteroid exception lowdose corticosteroid allow ) 10 . Known hypersensitivity monoclonal antibody biologic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>